Spots Global Cancer Trial Database for platinum refractory
Every month we try and update this database with for platinum refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor | NCT00543049 | Platinum Refrac... Primary Cancer ... Cancer of the F... | Sunitinib SUNITINIB | 18 Years - | AGO Study Group | |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | NCT01644825 | Ovarian Cancer | paclitaxel pazopanib | 18 Years - 75 Years | National Cancer Institute, Naples | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors | NCT02429466 | Germ Cell Tumor Testis Cancer Testicular Canc... | Guadecitabine (... | 18 Years - | Indiana University | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Cabazitaxel in Platinum Refractory Ovarian Cancer | NCT01747239 | Ovarian Cancer | Cabazitaxel | 18 Years - | Vejle Hospital | |
| GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | NCT02759588 | Ovarian Cancer Peritoneal Carc... Fallopian Tube ... | GL-ONC1 alone, ... | 21 Years - | Genelux Corporation | |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | NCT01644825 | Ovarian Cancer | paclitaxel pazopanib | 18 Years - 75 Years | National Cancer Institute, Naples | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
